154 related articles for article (PubMed ID: 29186201)
1. Prognostic markers for survival in patients with oligodendroglial tumors; a single-institution review of 214 cases.
Zetterling M; Berhane L; Alafuzoff I; Jakola AS; Smits A
PLoS One; 2017; 12(11):e0188419. PubMed ID: 29186201
[TBL] [Abstract][Full Text] [Related]
2. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of histomolecular subgroups of adult anaplastic (WHO Grade III) gliomas: applying the 'integrated' diagnosis approach.
Rajmohan KS; Sugur HS; Shwetha SD; Ramesh A; Thennarasu K; Pandey P; Arivazhagan A; Santosh V
J Clin Pathol; 2016 Aug; 69(8):686-94. PubMed ID: 26743027
[TBL] [Abstract][Full Text] [Related]
4. The oligodendroglial histological features are not independently predictive of patient prognosis in lower-grade gliomas.
Pareira ES; Shibuya M; Ohara K; Nakagawa Y; Kanazawa T; Kamamoto D; Kato Y; Arai E; Aimono E; Yoshida K; Nishihara H; Kanai Y; Sasaki H
Brain Tumor Pathol; 2022 Apr; 39(2):79-87. PubMed ID: 35292862
[TBL] [Abstract][Full Text] [Related]
5. Ki-67 and MCM6 labeling indices are correlated with overall survival in anaplastic oligodendroglioma, IDH1-mutant and 1p/19q-codeleted: a multicenter study from the French POLA network.
Pouget C; Hergalant S; Lardenois E; Lacomme S; Houlgatte R; Carpentier C; Dehais C; Rech F; Taillandier L; Sanson M; Appay R; Colin C; Figarella-Branger D; Battaglia-Hsu SF; Gauchotte G
Brain Pathol; 2020 May; 30(3):465-478. PubMed ID: 31561286
[TBL] [Abstract][Full Text] [Related]
6. [Influence of molecular-genetic factors on prognosis in patients with oligodendroglial tumors].
Absaliamova OV; Korshunov AG; Loshakov VA; Kobiakov GL; Golanov AV; Urakov SV; Amanov RD; Lichinitser MR
Zh Vopr Neirokhir Im N N Burdenko; 2009; (1):17-23; discussion 23-4. PubMed ID: 19507310
[TBL] [Abstract][Full Text] [Related]
7. Deferred radiotherapy and upfront procarbazine-ACNU-vincristine administration for 1p19q codeleted oligodendroglial tumors are associated with favorable outcome without compromising patient performance, regardless of WHO grade.
Hata N; Yoshimoto K; Hatae R; Kuga D; Akagi Y; Suzuki SO; Iwaki T; Shono T; Mizoguchi M; Iihara K
Onco Targets Ther; 2016; 9():7123-7131. PubMed ID: 27895504
[TBL] [Abstract][Full Text] [Related]
8. The sinuous, wave-like intratumoral-wall sign is a sensitive and specific radiological biomarker for oligodendrogliomas.
Li M; Wang J; Chen X; Dong G; Zhang W; Shen S; Jiang H; Yang C; Zhang X; Zhao X; Zhu Q; Li M; Cui Y; Ren X; Lin S
Eur Radiol; 2023 Jun; 33(6):4440-4452. PubMed ID: 36520179
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical ATRX expression is not a surrogate for 1p19q codeletion.
Yamamichi A; Ohka F; Aoki K; Suzuki H; Kato A; Hirano M; Motomura K; Tanahashi K; Chalise L; Maeda S; Wakabayashi T; Kato Y; Natsume A
Brain Tumor Pathol; 2018 Apr; 35(2):106-113. PubMed ID: 29550880
[TBL] [Abstract][Full Text] [Related]
10. Relationship between radiological characteristics and combined 1p and 19q deletion in World Health Organization grade III oligodendroglial tumours.
Kim JW; Park CK; Park SH; Kim YH; Han JH; Kim CY; Sohn CH; Chang KH; Jung HW
J Neurol Neurosurg Psychiatry; 2011 Feb; 82(2):224-7. PubMed ID: 20587495
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the impact of glioma diagnostic reclassification following the new 2016 WHO classification on a series of cases.
Valera-Melé M; Mateo Sierra O; Sola Vendrell E; Guzmán de Villoria L JA; Carvajal Díaz L; Gil de Sagredo Del Corral ÓL; García Leal R
Neurocirugia (Astur : Engl Ed); 2019; 30(1):19-27. PubMed ID: 30366644
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical markers for prognosis of oligodendroglial neoplasms.
Korshunov A; Golanov A; Sycheva R
J Neurooncol; 2002 Jul; 58(3):237-53. PubMed ID: 12187958
[TBL] [Abstract][Full Text] [Related]
13. Radiomics and Qualitative Features From Multiparametric MRI Predict Molecular Subtypes in Patients With Lower-Grade Glioma.
Sun C; Fan L; Wang W; Wang W; Liu L; Duan W; Pei D; Zhan Y; Zhao H; Sun T; Liu Z; Hong X; Wang X; Guo Y; Li W; Cheng J; Li Z; Liu X; Zhang Z; Yan J
Front Oncol; 2021; 11():756828. PubMed ID: 35127472
[TBL] [Abstract][Full Text] [Related]
14. Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors.
Panageas KS; Reiner AS; Iwamoto FM; Cloughesy TF; Aldape KD; Rivera AL; Eichler AF; Louis DN; Paleologos NA; Fisher BJ; Ashby LS; Cairncross JG; Urgoiti GB; Wen PY; Ligon KL; Schiff D; Robins HI; Rocque BG; Chamberlain MC; Mason WP; Weaver SA; Green RM; Kamar FG; Abrey LE; DeAngelis LM; Jhanwar SC; Rosenblum MK; Lassman AB
Neuro Oncol; 2014 Nov; 16(11):1541-6. PubMed ID: 24997140
[TBL] [Abstract][Full Text] [Related]
15. Classification of oligodendroglial tumors based on histopathology criteria is a significant predictor of survival--clinical, radiological and pathologic long-term follow-up analysis.
Sepulveda Sanchez JM; Martinez Montero JC; Diez-Lobato R; Hernandez-Lain A; Cabello A; Ramos A; Gonzalez Leon P; Ricoy Campo JR
Clin Neuropathol; 2009; 28(1):11-20. PubMed ID: 19216215
[TBL] [Abstract][Full Text] [Related]
16. Oligodendroglial tumors with marked desmoplasia: clinicopathologic and molecular features of 7 cases.
Jentoft M; Giannini C; Rossi S; Mota R; Jenkins RB; Rodriguez FJ
Am J Surg Pathol; 2011 Jun; 35(6):845-52. PubMed ID: 21552114
[TBL] [Abstract][Full Text] [Related]
17. [Implication of radiological pattern in the prognosis of oligodendroglial tumors: correlation with genetic profile].
Brell M; Castañer S; Pujol-Farré T; Boluda S; Ribalta T; Bruna J; Martínez M; Verger E; Villà S; Viñolas N; Gil M; Graus F; Tortosa-Moreno A
Rev Neurol; 2011 Apr; 52(8):465-71. PubMed ID: 21425099
[TBL] [Abstract][Full Text] [Related]
18. [The clinical relevance of 1p19q codeletion of oligodendrogliomas at the Department of Neurosurgery in Debrecen].
Klekner A; Fekete G; Rencsi M; Méhes G; Szabó P; Bognár L
Ideggyogy Sz; 2012 Jan; 65(1-2):17-24. PubMed ID: 22338842
[TBL] [Abstract][Full Text] [Related]
19. New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951.
Gorlia T; Delattre JY; Brandes AA; Kros JM; Taphoorn MJ; Kouwenhoven MC; Bernsen HJ; Frénay M; Tijssen CC; Lacombe D; van den Bent MJ
Eur J Cancer; 2013 Nov; 49(16):3477-85. PubMed ID: 23896377
[TBL] [Abstract][Full Text] [Related]
20. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ
Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
